The company behind a salvia-based drug that was approved by the Federal Government last month is preparing to test the drug for its CBD properties, including CBD in cannabis.
The Australian Medicines and Healthcare products Regulatory Agency has been notified of the proposed test.
Key points:The test will be conducted at the company’s lab in Sydney’s CBD, and could take up to 12 months to completeThe company, which was originally based in New South Wales, has been working on a CBD drug for more than five yearsThe company is hoping to test for the drug in the US soonMr Kynoch said it was not yet clear if the test would be conducted in the CBD or the city.
“We are still looking into that,” he said.
“It is a very complicated area, the potential for a lot of unknowns.”
Mr Klenoch said the company had not yet decided whether to proceed with the test, but the test was expected to take up 12 months.
“That is what we are doing right now,” he told AAP.
“Hopefully, we can start to test in early December, probably the end of the year.”
He said it would take between 18 months and a year to complete the test.
“This is a major undertaking, and we are just at the beginning stages,” he added.
“If it does go ahead, it could take us six to 12 weeks.”
Salvia, a plant that contains the psychoactive compound cannabidiol, is used for medicinal purposes in the United States.CBD is the compound found in the plant’s leaves.
In Australia, cannabichromene (CBC) is the active ingredient in salvia.
Its production is regulated under the Pharmaceutical Benefits Scheme.
The drug has been approved for sale in Australia and New Zealand.ABC/AAP